Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Guselkumab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07746765
What this trial is testing

Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting

Who this might be right for
Crohn DiseaseColitis, Ulcerative
Janssen Sciences Ireland UC 35
Post-approval studies (Phase 4)Looking for participantsNCT05858632
What this trial is testing

Immune Spatial Features of Guselkumab Cutaneous Response

Who this might be right for
Psoriasis of Scalp
University of California, San Francisco 10
Post-approval studies (Phase 4)Study completedNCT04645355
What this trial is testing

Guselkumab Immunogenetics

Who this might be right for
Psoriasis GuttatePlaque Psoriasis
University of California, San Francisco 17
Post-approval studies (Phase 4)Study completedNCT04080648
What this trial is testing

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

Who this might be right for
Psoriasis Vulgaris
University Hospital, Ghent 79
Not applicableEnded earlyNCT07449234
What this trial is testing

Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Who this might be right for
Psoriasis
Janssen-Cilag Ltd. 9
Early research (Phase 1)Study completedNCT02397382
What this trial is testing

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Who this might be right for
Psoriasis
Janssen Research & Development, LLC 16
Testing effectiveness (Phase 2)Ended earlyNCT04376827
What this trial is testing

Guselkumab in Participants With Active Lupus Nephritis

Who this might be right for
Lupus Nephritis
Janssen Research & Development, LLC 33
Large-scale testing (Phase 3)Study completedNCT03162796
What this trial is testing

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

Who this might be right for
Arthritis, Psoriatic
Janssen Research & Development, LLC 383
Testing effectiveness (Phase 2)Study completedNCT02319759
What this trial is testing

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Who this might be right for
Psoriatic Arthritis
Janssen Research & Development, LLC 149
Post-approval studies (Phase 4)Ended earlyNCT04533737
What this trial is testing

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

Who this might be right for
Plaque PsoriasisPsoriasis VulgarisPsoriasis
LEO Pharma 113
Large-scale testing (Phase 3)Study completedNCT04397263
What this trial is testing

Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Who this might be right for
Crohns Disease
Janssen Pharmaceutical K.K. 38
Large-scale testing (Phase 3)Ended earlyNCT05784129
What this trial is testing

Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

Who this might be right for
Crohn's Disease
Janssen Research & Development, LLC 4
Not applicableLooking for participantsNCT07302360
What this trial is testing

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

Who this might be right for
Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd. 200
Testing effectiveness (Phase 2)Study completedNCT03553823
What this trial is testing

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Who this might be right for
Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 40
Post-approval studies (Phase 4)Ended earlyNCT05125679
What this trial is testing

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Janssen-Cilag Ltd. 15
Not applicableLooking for participantsNCT07487480
What this trial is testing

A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab

Who this might be right for
Inflamatory Bowel DiseaseInflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Second Affiliated Hospital, Zhejiang University, School of Medicine 60
Large-scale testing (Phase 3)Looking for participantsNCT05669833
What this trial is testing

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Who this might be right for
Psoriatic Arthritis
University of Pennsylvania 63
Post-approval studies (Phase 4)Study completedNCT04914429
What this trial is testing

Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Janssen Research & Development, LLC 327
Large-scale testing (Phase 3)Study completedNCT04936308
What this trial is testing

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Who this might be right for
Arthritis, Psoriatic
Janssen Research & Development, LLC 453
Large-scale testing (Phase 3)Active Not RecruitingNCT05197049
What this trial is testing

Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Who this might be right for
Crohn Disease
Janssen Research & Development, LLC 350
Next Page